Improved Protease Partner Programs
Wyeth
Catalyst signed a worldwide exclusive licensing agreement Wyeth Pharmaceuticals on 29 June 2009. Catalyst will be responsible for discovery and research of novel FVIIa variants, including improved FVIIa proteases that may potentially allow their use in a prophylactic setting for hemophilia patients and for the control of bleeding in normal patients in a surgical or trauma setting. Wyeth will be responsible for preclinical and clinical development, manufacturing and commercialization of resulting FVIIa products.
Alterase™ Therapeutics Partner Programs
MedImmune
Catalyst Biosciences partnered with MedImmune in June 2009 to discover and develop Alterase™ Therapeutics targeting up to two undisclosed targets, one of which is in inflammatory and autoimmune diseases.
